Cardiovascular disease mortality has decreased over the past 30 years. Between 1970 and 2000. Life expectancy from cardiovascular disease in America increased by three years. This growing optimism is support many epidemiological studies. That support this clear evolution. Root cause analysis leads to improved quality of treatment and care as the main reason. The success rate is between 50-75% depending on the sample tested. And the rest relates to the quality of life and changes in protection. Cardiovascular translational studies and the development of many elements. CVD has led to this success. The identification and development of effective and safe.
Thrombolytic agents during acute coronary events as well as percutaneous. Coronary intervention with stent implantation has contributed to acute mortality and myocardial salvage. Statins are important in preventing the spread of atherosclerotic disease. And are also known for their broad spectrum of action. In cardiovascular disease, beta-blockers. And ACE inhibitors have improved life expectancy by leaps and bounds. Although many of these improvements are the result of therapeutic advances. Including statins, from the classic bench. Others recognize more cautious advances, such as beta-blockers.
The development of treatments in other areas. Is less interesting and full of complications. The development of antiarrhythmic agents. Has made great strides from simple data to structure. and function of cardiac ion channels. But the translation into direct pharmacology has. Shown an unexpected arrhythmic risk for class III ion channel blockers. Automated defibrillators play an important role in treating life. Threatening arrhythmias and saving lives, but are not available.
The image of this second option reflects the deeper. The darker side of this medical breakthrough:
Is the increased life expectancy of CVD patients with high financial costs. In the United States, CVD hospitalizations have tripled. And medical costs are estimated at $386 billion. In 2006, the annual cost of medical care for CVD was less than £110 billion. It accounts for most of the cost of surgery, systemic therapy, and imaging. The ageing population is without further progress in treatment and prevention. This will lead to a significant increase in the incidence of CWD. This is evident in the domestic indicators of the last decade. This shows that the mortality rate has decreased but the prevalence has increased.
Also, the incidence of CWD increased in areas. With poor healthcare coverage and expect to increase. The World Health Organization estimates the increase in life expectancy. And adverse trends in cardiovascular risk factors. Together with obesity and type II diabetes, this could lead to a doubling of CVD prevalence by 2050.
Thus, there is a clear imperative to improve our CVD practice. And continue to invest in direct cardiovascular translational research. Too to the great need, the proposed development is a strong incentive. To rank cardiovascular research based on these remarkable results. The new paradigm is health promotion and early intervention in the treatment of CVD. This can result in higher quality care. For a greater number of patients, including cost savings. This requires individuals to
(i) improve the physiological and molecular understanding of health and disease mechanisms. So that they can apply earlier preventive interventions and better diagnosis and treatment,
(ii) develop prevention and treatment plans, and
(iii) finally We will use knowledge. We are improving the data translation process to speed up implementation.
.jpg)
Comments
Post a Comment